segunda-feira, 5 de outubro de 2026
PesquisarExplore
Inteligência rastreável à fonte

Notícias em que pode confiar

Cada facto rastreado até à sua fonte, e verificado. Explore as empresas, os factos e as conclusões por trás das notícias.

O que estamos a observar

Conclusões que a nossa IA está a tirar dos factos rastreados — leia-as como interpretação, cada uma sustentada nos dados e nas entidades que menciona.

trend· bullish

Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave

Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.

Novo NordiskEli LillyMER51152-week fMRI study of CagriSema
transformation· bullish

Agentic AI Moves Into the Enterprise Stack: Big Tech Enters, Startups Fund Up, Incumbents Defend

Enterprise software is being reshaped by agentic AI. Meta is entering the market with a Meta Enterprise Platform led by MongoDB's departing CEO. Capital is flowing to AI-native vertical startups (Dextr AI, Latitude, Freehand, Groq), and incumbents are responding through guidance raises (UiPath), security M&A (Fortinet/Virtue AI) and cloud growth (Alphabet, +82%). Investors such as Norwest see finance and ERP back-office software as the next area to be disrupted, while governance, data sovereignty and AI's weakness at calculation are seen as limits on adoption in regulated finance.

Meta Enterprise PlatformDextr AIEnterprise AI Agentic MarketSprinklr, Inc.
transformation· bullish

Q4 2026 Leadership Succession and Board Renewal Wave

A cluster of orderly CEO handoffs and board refreshes runs from late September into early October 2026. Mattel (Kreiz to Lynch), Verra Mobility (Keyser to Newhard), Heineken, Brown-Forman and BellRing all announced new leaders, usually with outgoing executives staying on as advisors. In parallel, boards are managing shareholder-vote events: NGEx's spin-out, Silvercorp's articles amendment, Kneat's sale process after a broad sponsor and strategic canvass, and the amended onsemi–Synaptics merger. Governance language stresses continuity, independent validation (ISS) and process rigor, and the framing is largely positive.

Judy OlianDiana FergusonVerra Mobility Board of DirectorsPatrick Byrne
cycle· mixed

K-Shaped Market: AI Infrastructure Optimism vs. Consumer Strain

Analyst activity in mid-2026 shows a split market. AI-infrastructure and frontier-tech names get bullish coverage: Micron and Sandisk (Lynx), ASML's 4% sympathy rally, Digital Realty's raised FFO guidance, Bloom's dispatchable power for data centers, NuScale (BofA buy), and Iovance (Goldman buy). Valuation caution runs alongside it, with D-Wave at 171x sales and SpaceX down more than 40% from its highs. Consumer and retail names are weaker: Wendy's fell nearly 6% and its take-private was abandoned, GAP cut traffic guidance, Nike's recovery is slow, Levi's fell despite a beat, and Capital One is exposed to the K-shaped economy at lower incomes.

K.C. RajkumarRinny SinghMelissa TuckerMarc Gerstein
transformation· bullish

Oncology's AI-Driven Pipeline Race: Combination Immunotherapy, mRNA Vaccines and Biotech Capital Discipline

Oncology is being reshaped by two forces. One is late-stage catalysts: the ivonescimab BLA with a PDUFA date of 2026-11-14, the Merck/Moderna personalized mRNA vaccine (intismeran) with data due at ESMO, and ivonescimab plus Datroway combinations in TNBC. The other is AI-first drug discovery, which AstraZeneca is pushing toward agentic, de novo biologics design. Commercial results are strong (Novocure's record quarter, raised hematology/oncology guidance, Arcalyst growth), while smaller biotechs focus on extending cash runways (ADC Therapeutics into 2028, Treeline via its deal with Standard BioTools). The fintech and trading link is indirect: the main finance signals are regulatory catalysts, guidance revisions and capital-raising or partnership deals, with AI cited as a driver of R&D productivity. The set includes unrelated items (rockets, Meta trial, dinosaurs) that don't belong to the narrative.

Personalized mRNA Skin Cancer VaccineDatroway (datopotamab deruxtecan)First-line triple-negative breast cancer (TNBC)Stage IIB-IV melanoma
cycle· mixed

AI Supercycle Meets Scrutiny: Memory Boom, Capex Bull Cases, and Governance Gaps

AI infrastructure demand is driving record results (Micron's record FY2026 and stronger FY2027 guidance, Alphabet's $701B-by-2029 bull case, hyperscaler backlogs, jumbo AI startup funding), while efficiency tooling (Multiverse's CompactifAI cutting Llama 3.3 70B latency roughly 48% and doubling throughput at scale) and new frontier models (Claude Opus 5.5) extend adoption. Alongside the boom, risks and oversight are emerging: unprecedented capex, legal and regulatory pressure, Pentagon AI lie-detector funding, AI agent governance and security startups, and AI literacy and watermarking efforts. Sentiment is bullish on fundamentals but tempered by capex and regulatory concerns.

Hyperscalers and AI CompaniesArtificial Intelligence sector fundingSuper Intelligence (SI)Enterprise AI Agentic Market
Sinais que acompanhamos
  • EPKINLY Regulatory-Clinical Success Cascade

    High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.

  • Satellite-Terrestrial Network Integration Acceleration

    Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases

  • Smart Home AI Platform Convergence

    Samsung will likely announce a unified smart home AI platform or hub within 2-3 months that connects these disparate AI-enabled products

  • AI Integration Acceleration

    Sustained AI feature expansion across Samsung ecosystem in Q1-Q2 2026, with likely follow-up announcements for mobile devices and additional appliances

Hipóteses em estudo
  • NVIDIA GPU acceleration is becoming the dominant infrastructure for AI chip design and EDA workflows, creating a self-reinforcing ecosystem where AI chips are designed using AI-accelerated tools

    88% confidence · por testar
  • Data center infrastructure investments are shifting from traditional cloud providers to AI-specific facilities, with hyperscalers willing to commit $20B+ multi-year contracts for AI-optimized data center capacity, creating opportunities for specialized infrastructure developers

    88% confidence · por testar
  • LLM sycophancy is primarily caused by reinforcement learning from human feedback (RLHF) optimization for user approval rather than truthfulness, creating a systematic bias that degrades model reliability in extended conversations

    85% confidence · por testar
  • AI safety concerns are escalating as models gain access to classified and sensitive data, creating new security vulnerabilities and ethical challenges around training data governance

    85% confidence · por testar
  • Hyperscaler AI infrastructure investments exceeding $200B combined will drive semiconductor demand and AI chip production capacity expansion in 2026

    85% confidence · por testar
Sources we've traced
all →
Source document

Stock market today: Dow, S&P 500, Nasdaq edge higher in volatile trading as Wall Street assesses AI fears

“Stock market today: Dow, S&P 500, Nasdaq edge higher in volatile trading as Wall Street assesses AI fears US stocks edged higher Tuesday in volatile trading as Wall Street continued assessing the AI jitters that have hammered markets in recent weeks…”

Source document

Solidt resultat for 2025 på baggrund af god kundeaktivitet og stærk kreditkvalitet Resultat efter skat på 23,0 mia. kr. Udbytte for 2025 på 16,94 kr. pr. aktie samt et ekstraordinært udbytte på 5,78 kr. pr. aktie, samlet 22,72 kr. pr. aktie

“Solidt resultat for 2025 på baggrund af god kundeaktivitet og stærk kreditkvalitet Resultat efter skat på 23,0 mia. kr. Udbytte for 2025 på 16,94 kr…”

Source document

St. Joe Q4 Earnings Call Highlights

“St. Joe Q4 Earnings Call Highlights St. Joe logo Key Points Strong Q4 and full-year performance: St. Joe posted a 24% revenue increase in Q4 and full-year revenue rose 27% to $513.2M, with net income up 56% to $115.6M and EPS of $2.00, supported by a shift to 56% recurring revenue…”

Source document

UK BNPL regulation – industry reaction

“UK BNPL regulation – industry reaction The UK’s Financial Conduct Authority has confirmed its final rules on Buy Now, Pay Later regulation. From 15 July, consumers will benefit from strengthened protections, including affordability checks and access to the financial ombudsman…”

Source document

Dave Announces Pricing of $175 Million 0% Convertible Notes

“Dave Announces Pricing of $175 Million 0% Convertible Notes Company entered into capped call transactions to increase effective conversion premium to 100% Company to repurchase approximately 334,000 shares of common stock using approximately $70.5 million of net proceeds Los Angeles, March 05, 2026 (GLOBE NEWSWIRE) --…”

Source document

Harness Therapeutics Nominates HRN001, a First-in-Class Drug Candidate for Huntington’s Disease and Establishes Clinical Advisory Board

“Harness Therapeutics Nominates HRN001, a First-in-Class Drug Candidate for Huntington’s Disease and Establishes Clinical Advisory Board HRN001 is a potent and specific antisense oligonucleotide designed to drive controlled upregulation of FAN1, a genetically validated target in Huntington’s disease Clinical Advisory Bo…”

Onde as fontes discordam
all →
Shopify Inc.

Two different margin values (16% vs 18%) are recorded for the same entity (Shopify Inc.) at the identical timestamp (2026-08-05 00:00:00). With no distinguishing context (same period designation, no qualifier for margin type), these represent conflicting data about the same fact.

Citigroup Inc.

Both facts measure EPS for Citigroup with identical observation dates (2025-12-31). FACT A explicitly specifies FY 2025 annual EPS at 6.99 USD/share, while FACT B reports 1.65 USD with an unspecified fiscal period (N/A). The values differ by a factor of ~4.2x, which is too large to explain by rounding, methodology, or data quality variance. While FACT B's 'N/A' fiscal period introduces ambiguity about whether it represents the same annual period, both observations are timestamped identically and purport to measure the same metric on the same date. If both represent FY 2025 annual EPS, this is a direct value conflict. If FACT B represents a different period (e.g., quarterly, TTM, or interim), the ambiguous labeling still constitutes a data quality issue that obscures the reconciliation.

Apple Inc.

The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.

Tesla Inc.

Both facts measure the same attribute (cash) for the same entity (Tesla Inc.) at the same point in time (2025-12-31). Although labeled with different fiscal period categories (FY 2025 vs Q4 2025), both periods end on the same date, making them equivalent time snapshots. The values differ drastically: $16.513 billion vs $44.06 USD. Since Q4 2025 is the final quarter of FY 2025, both should report identical cash balances at period-end. A 375 million-fold magnitude difference indicates a real contradiction, likely caused by a data quality issue (unit error, miscategorization, or source error in FACT B).

Tesla Inc.

Both facts report EPS (earnings per share) for Tesla Inc. for the identical fiscal period (Q1 2026) and observation date (2026-03-31), but state conflicting values: 0.13 USD/share vs. 0.41 USD. Same entity, same metric, same time period, different reported values.

ING Group

Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.

Every fact is traceable to the document it came from — see how we source every claim.

Latest News

View All →
Correção nas ações de chips de IA não freia acordos bilionários, consolidação e aposta estatal dos EUA
Analysis

Correção nas ações de chips de IA não freia acordos bilionários, consolidação e aposta estatal dos EUA

Wall Street corrigiu duramente os papéis de semicondutores de IA no fim de julho, mas os dados por trás do tombo mostram fornecimento garantido à Nvidia, dinheiro público entrando na GlobalFoundries e a fusão Skyworks-Qorvo já com liderança definida. Para o Brasil e Portugal, sem números locais no dossiê, o caso vale como estudo de caso de política industrial e de risco em ETFs alavancados.

LM Salvado•
Banco Central do Brasil mantém juros enquanto guerra no Irã adiciona riscos à inflação global
Política Monetária

Banco Central do Brasil mantém juros enquanto guerra no Irã adiciona riscos à inflação global

O Banco Central do Brasil interrompeu cortes de juros em março de 2026, citando novos riscos geopolíticos do conflito no Irã. O diretor de política monetária Nilton David alertou que a guerra pode exigir recalibração da estratégia de juros após a reunião de março, enquanto bancos centrais globais incluindo Fed e BCE também pausam reduções.

Nubank processa 100+ produtos em 2025 com IA, mas regulação FGTS freia crescimento de carteira para 10%
Fintech e Crédito Digital

Nubank processa 100+ produtos em 2025 com IA, mas regulação FGTS freia crescimento de carteira para 10%

O Nu Holdings lançou seu modelo de IA nuFormer em 2025, processando mais de 100 produtos e recursos. A ferramenta acelerou aquisição de clientes, mas mudanças na regulação do FGTS em novembro reduziram o crescimento esperado da carteira de 13-14% para 10%. Inter & Co captou 7 milhões de novos clientes em 2025, com coortes recentes transacionando mais rápido.

Investimentos de US$ 109 bilhões da Petrobras no pré-sal enfrentam risco de ativos encalhados
Energia e Transição

Investimentos de US$ 109 bilhões da Petrobras no pré-sal enfrentam risco de ativos encalhados

O plano de investimento 2026-2030 da Petrobras concentra US$ 109 bilhões em projetos de pré-sal de longa duração, mas enfrenta risco de ativos encalhados se a transição energética acelerar. Barris de águas profundas de alto custo podem se tornar antieconômicos contra fornecimento marginal em cenários de destruição acelerada de demanda por petróleo.

Ypê opera ERP sem suporte oficial da SAP e expõe cadeia de suprimentos a vulnerabilidades críticas
Enterprise Security

Ypê opera ERP sem suporte oficial da SAP e expõe cadeia de suprimentos a vulnerabilidades críticas

A Ypê, presente em 95% dos lares brasileiros, mantém sistemas SAP em suporte terceirizado via Rimini Street, sem acesso às correções de segurança oficiais do fornecedor. A estratégia deixa o ambiente ERP exposto a CVEs conhecidas que a SAP corrige, mas terceiros podem não replicar na mesma velocidade ou escopo. Especialistas classificam o risco como catastrófico em cenário de ataque direcionado.

Feito também para máquinas

Cada facto aqui é estruturado e rastreado à fonte — para que os sistemas de IA herdem a verdade de base, não afirmações reformuladas. Os mesmos factos que uma pessoa lê, um modelo pode consultar.

Obtenha via API →
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,340 documentos-fonte arquivados
Consulte estes dados → isubstrate.com